Project Details
Project description 

1/ A sanitary challenge, an economic opportunity. COPD is considered by the World Health Organization as the third leading cause of death worldwide, causing 3.23 million deaths in 2019 (5.3% of all deaths) and this even though underdiagnosis and under-reporting of COPD are universal. COPD affects up to 384 million patients globally, with an overall mortality rate of 60 per 100,000 people per year in ERS (European Respiratory Society, 2015).
- In the EU, it is estimated that spending on inpatient, outpatient and pharmaceuticals exceed €10bn per year, productivity losses are at €28.5bn year, and 300,000 are premature deaths (European Respiratory Society).
- The raise of AI and DeepTech models open the door to a tailor-made approach to patients and dramatically raised the prospects of preventive care.
2/ Cross-regional scaling: DIGILUNG. DIGILUNG takes a new step in Personalised medicine to address the global challenge of COPD. DIGILUNG taps into the sourcing of technological capabilities from advanced, less advanced and transition regions to scale-up 3 key industrial pilots (through TRL7-8 up to market uptake) and develop an integrated solution for their sustainable integration over time. DIGILUNG will scale up 3 AI-based innovations from 3 business-driven pilots, and further their deployment by building a holistic solution that will link them to each other. It will consist of a state-of-the-art, open, and interoperable digital device (powered by the integrative solution from Cognuse) through which the connected LungShirt of ASTRIDE (Kinetic Analysis), worn daily by the patient, will record breathing and activity data from patients before sending them to the MoveUp AI platform for analysis, interpretation, visualisation, and recommendation.
3/ Besides reinforcing therapy ownership by the patient and allowing for live rehab, DIGILUNG will generate a wide range of spill- over effects: productivity gains, reduce cost of COPD, and generate new data & tech

Runtime: 2023 - 2026